Teva Pharmaceutical Industries Ltd. ADR (TEVA): Price and Financial Metrics


Teva Pharmaceutical Industries Ltd. ADR (TEVA): $9.24

0.29 (+3.24%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

TEVA POWR Grades


  • Value is the dimension where TEVA ranks best; there it ranks ahead of 98.29% of US stocks.
  • TEVA's strongest trending metric is Momentum; it's been moving down over the last 48 weeks.
  • TEVA ranks lowest in Momentum; there it ranks in the 13th percentile.

TEVA Stock Summary

  • TEVA's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.43 -- higher than only 2.7% of US-listed equities with positive expected earnings growth.
  • TEVA's price/sales ratio is 0.61; that's higher than the P/S ratio of merely 12.72% of US stocks.
  • Over the past twelve months, TEVA has reported earnings growth of -586.16%, putting it ahead of merely 3.61% of US stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Teva Pharmaceutical Industries Ltd, a group of peers worth examining would be PAAS, EGY, CCMP, KRA, and SSYS.
  • TEVA's SEC filings can be seen here. And to visit Teva Pharmaceutical Industries Ltd's official web site, go to www.tevapharm.com.

TEVA Valuation Summary

  • TEVA's EV/EBIT ratio is -11.9; this is 140.61% lower than that of the median Healthcare stock.
  • Over the past 227 months, TEVA's price/earnings ratio has gone down 27.
  • TEVA's price/earnings ratio has moved down 27 over the prior 227 months.

Below are key valuation metrics over time for TEVA.

Stock Date P/S P/B P/E EV/EBIT
TEVA 2021-08-31 0.6 1 -2.7 -11.9
TEVA 2021-08-30 0.6 1 -2.6 -11.9
TEVA 2021-08-27 0.6 1 -2.6 -11.9
TEVA 2021-08-26 0.6 1 -2.6 -11.9
TEVA 2021-08-25 0.6 1 -2.7 -12.0
TEVA 2021-08-24 0.6 1 -2.7 -12.0

TEVA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • TEVA has a Quality Grade of C, ranking ahead of 54.74% of graded US stocks.
  • TEVA's asset turnover comes in at 0.329 -- ranking 139th of 677 Pharmaceutical Products stocks.
  • DARE, WINT, and PBYI are the stocks whose asset turnover ratios are most correlated with TEVA.

The table below shows TEVA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.329 0.469 -0.088
2021-03-31 0.319 0.463 -0.097
2020-12-31 0.316 0.464 -0.102
2020-09-30 0.298 0.471 -0.108
2020-06-30 0.293 0.462 0.018
2020-03-31 0.295 0.457 -0.010

TEVA Stock Price Chart Interactive Chart >

Price chart for TEVA

TEVA Price/Volume Stats

Current price $9.24 52-week high $13.30
Prev. close $8.95 52-week low $8.24
Day low $8.94 Volume 9,845,400
Day high $9.45 Avg. volume 8,860,294
50-day MA $9.36 Dividend yield N/A
200-day MA $10.43 Market Cap 10.09B

Teva Pharmaceutical Industries Ltd. ADR (TEVA) Company Bio


Teva Pharmaceutical Industries Ltd is a pharmaceutical company which develops, produces, and markets, generic and specialty medicines which include chemical and therapeutic medicines in a variety of dosage forms and central nervous system medicines. Established in 1901, the company markets 3,500 generic and proprietary products to 60 countries worldwide. Teva competes against other large pharmaceutical companies such as Pfizer, Merck, Novartis, and GlaxoSmithKline. Kare Schulz currently serves as Teva’s President, Chairman of the Board, and Chief Executive Officer, overseeing an international workforce of around 38,000 employees.


TEVA Latest News Stream


Event/Time News Detail
Loading, please wait...

TEVA Latest Social Stream


Loading social stream, please wait...

View Full TEVA Social Stream

Latest TEVA News From Around the Web

Below are the latest news stories about Teva Pharmaceutical Industries Ltd that investors may wish to consider to help them evaluate TEVA as an investment opportunity.

Neutropenia Biologic Drug Treatment Global Market Report 2021: COVID-19 Growth And Change To 2030

Major players in the neutropenia biologic drug treatment market are Teva Pharmaceutical, Amgen, Sanofi, Mylan, Kyowa Kirin, Baxter International, CVS Health Corp, Novartis, Spectrum Pharmaceuticals, and Partner Therapeutics. Major players in the neutropenia biologic drug treatment market are Teva Pharmaceutical, Amgen, Sanofi, Mylan, Kyowa Kirin, Baxter International, CVS Health Corp, Novartis, Spectrum Pharmaceuticals, and Partner Therapeutics.

Intrado Digital Media | September 24, 2021

Global Sennetsu Fever Treatment Market Business Growth Statistics and Key Players Insights 2021-2028||Abbott, Bayer AG, Mylan N.V., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Allergan, Merck Sharp & Dohme Corp

Global sennetsu fever treatment market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to account to grow at a CAGR of 3.90% in the above mentioned forecast

OpenPR | September 22, 2021

United States: Obviousness Of Method Claim Requires Expectation Of Success For Recited Purpose - Foley & Lardner

In Eli Lilly and Co. v. Teva Pharmaceuticals International GmbH, the Federal Circuit affirmed the USPTO Patent Trial and Appeal Board decision upholding Teva''s patents directed to specific methods of treatment

Mondaq | September 21, 2021

Federal Circuit Vacates Judgment, Reinstates Jury''s Verdict of Induced Infringement

Background - On August 5, 2021, the Federal Circuit issued an opinion in GlaxoSmithKline v. Teva Pharmaceuticals, Case No. 18-1976, in favor of GSK, finding that Teva was liable for inducing infringement of GSK''s patent. This decision reversed the grant of judgment as a matter of law ("JMOL") that was entered by the trial court below and reinstated the jury''s verdict for GSK. By: Jones Day

JD Supra | September 21, 2021

15 Best Stocks to Invest in Today According to David Abrams

In this article, we discuss the 15 best stocks to invest in today according to David Abrams based on Q2 holdings of the fund. If you want to skip our detailed analysis of Abrams’ history, investment philosophy, and hedge fund performance, go directly to the 5 Best Stocks to Invest in Today According to David […]

Yahoo | September 20, 2021

Read More 'TEVA' Stories Here

TEVA Price Returns

1-mo -1.18%
3-mo -6.67%
6-mo -19.51%
1-year 5.00%
3-year -57.10%
5-year -79.31%
YTD -4.25%
2020 -1.53%
2019 -36.45%
2018 -18.63%
2017 -46.23%
2016 -43.44%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8366 seconds.